AllSci News
Junshi Bio, Antengene pair PD-1/VEGF bispecific with oral CD73 inhibitor in China-focused deal
Shanghai Junshi Biosciences Co., Ltd (HKEX: 1877; SSE: 688180) and Antengene Corporation Ltd (SEHK: 6996.HK) entered into a strategic clinical collaboration to…
Larimar’s nomlabofusp takes BTD status for Friedreich’s ataxia ahead of June BLA filing
Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, announced receipt of US FDA Breakthrough Therapy Designation…
Akebia Therapeutics puts HIF inhibitor into first-in-human for acute kidney injury
Akebia Therapeutics has moved pipeline candidate AKB-9090, an intravenous hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, into a Phase I first-in-human clinical trial…
Novo Nordisk’s China partner posts strong Phase II data for triple incretin agonist
Novo Nordisk announced that its China-based partner United Bio-Technology’s investigational triple incretin receptor agonist UBT251 met the primary endpoint in a randomized…
Astellas puts up USD 335m for Vir Bio’s masked PSMA T-cell engager in prostate cancer
Astellas Pharma Inc. (TSE: 4503) and Vir Biotechnology, Inc. (Nasdaq: VIR) signed a global strategic collaboration deal that will see Astellas gain…
Ultragenyx files gene therapy for US approval in glycogen storage disease
US-based biotech Ultragenyx Pharmaceutical Inc., (NASDAQ: RARE) announced that the US FDA has accepted a Biologics License Application (BLA) for DTX401 (pariglasgene…
Pfizer to commercialize Sciwind’s on-market GLP-1 ecnoglutide in China
China-based Hangzhou Sciwind Biosciences Co., Ltd announced a commercialization collaboration with Pfizer China for ecnoglutide, a cAMP-biased glucagon-like peptide-1 (GLP-1) receptor agonist,…
Harbour BioMed forms ‘new co.’ Solstice Onco focused on CTLA-4 antibody
China-based Harbour BioMed signed an exclusive licensing and equity partnership deal with US-based Solstice Oncology for the development and commercialization of HBM4003,…
Roche drops satralizumab development for Duchenne Muscular Dystrophy
Roche has terminated recruitment in the Phase II SHIELD DMD study (NCT06450639) evaluating satralizumab (trade name: Enspryng), an interleukin-6 (IL-6) receptor-targeting monoclonal…
Vanda takes FDA approval for Bysanti as 1st-line schizophrenia, bipolar therapy
US-based Vanda Pharmaceuticals unveiled US FDA approval for Bysanti (milsaperidone) indicated to treat schizophrenia in adults and the acute treatment of manic…
Gossamer’s seralutinib falls at Phase III stage in PAH
US-based Gossamer Bio revealed that its pipeline candidate seralutinib, an inhaled PDGFR/CSF1R/c-KIT inhibitor, has failed to achieve the primary endpoint in a…
Palisade Bio Launches Phase Ib Trial of PALI-2108 for Fibrostenotic Crohn’s Disease
Palisade Bio (Nasdaq: PALI) has opened enrollment in a Phase Ib clinical trial evaluating PALI-2108, a first-in-class oral PDE4 inhibitor prodrug, in…
Gilead seeks full control of BCMA CAR-T franchise via USD 7.8b acquisition of Arcellx
Gilead Sciences has agreed to acquire US-based clinical-stage cell therapy developer Arcellx for an implied equity value of USD 7.8 billion in…
Novo Nordisk’s CagriSema misses non-inferiority endpoint in head-to-head trial vs. tirzepatide
Novo Nordisk released headline data from the Phase III REDEFINE 4 study for CagriSema in obesity, in which the fixed dose combination…
Regeneron’s garetosmab gains FDA priority review for ultra rare disease FOP
Regeneron Pharmaceuticals (Tarrytown, New York; NASDAQ: REGN) announced that the US FDA has accepted for Priority Review its Biologics License Application for…
The AllSci Brief
Free, systematic R&D and deal news. Daily.